In a recent LinkedIn post, Dr. Martha Boeckenfeld highlights the critical role of robust technological infrastructure in bringing breakthrough therapies to patients, particularly in the realm of rare diseases. Dr. Boeckenfeld uses the example of CSL Behring and their partnership with AWS to illustrate how modernizing legacy systems can dramatically improve the speed and efficiency of delivering life-changing treatments.
Dr. Boeckenfeld emphasizes that the pace of scientific advancement is often dictated by the underlying systems that support it. “Behind every breakthrough therapy is infrastructure that either accelerates or limits how fast science reaches patients,” she states, setting the stage for her analysis of CSL Behring’s transformation.
The Challenge of Legacy Infrastructure
CSL Behring, a company specializing in gene therapies and plasma-derived medicines for rare diseases and operating in over 100 countries, found its legacy infrastructure to be a significant bottleneck. Dr. Boeckenfeld points out that such established systems, while functional, can hinder the agility required in fast-moving scientific fields. This is a common challenge for large organizations that have grown over time.
Rebuilding with Cloud Technology
To overcome these limitations, CSL Behring partnered with AWS to rebuild its foundational IT infrastructure. Dr. Boeckenfeld details the scale of this migration:
“5,000+ VMware servers across 29 data centers migrated to AWS”
This foundational shift enabled significant improvements in operational efficiency. According to Dr. Boeckenfeld, the migration led to tangible results, including:
- 12x faster application discovery
- 30% lower operating costs
- On track to exit 17 data centers in 30 months
“The results: 12x faster application discovery, 30% lower operating costs, and on track to exit 17 data centers in 30 months,” Dr. Boeckenfeld shares, underscoring the immediate impact of the cloud migration.
Impact on Patient Outcomes
Dr. Boeckenfeld strongly connects these operational improvements directly to patient outcomes, arguing that the speed gained in development and delivery is paramount for those suffering from rare diseases. She illustrates this with a powerful patient story, detailing the experience of a hemophilia B patient who received CSL Behring’s HEMGENIX gene therapy.
A Life Transformed by Gene Therapy
The post recounts how a patient, who had spent decades managing the condition with frequent self-injections and constant fear of complications, experienced a life-altering change after a single, two-hour infusion of HEMGENIX. Dr. Boeckenfeld highlights the dramatic clinical improvements:
“Factor IX rose from under 1% to about 32%”
This single treatment enabled the patient to stop routine injections, experience normal healing, and resume activities like martial arts and dancing. Dr. Boeckenfeld frames this transformation as a direct consequence of CSL Behring’s enhanced operational capabilities, driven by their cloud infrastructure.
The Math of Accelerated Cures
Dr. Boeckenfeld simplifies the impact of accelerated delivery, stating, “The math is simple: 1 patient healed = proof 10 patients off needles = a new baseline.” She extends this logic to illustrate how scaling these successes can lead to profound societal benefits, enabling more children to grow up without the burden of weekly injections and speeding up the delivery of all therapies in the development pipeline.
Ultimately, Dr. Boeckenfeld concludes that rare diseases require swift delivery of cures rather than prolonged discussions. “Rare diseases don’t need more slide decks. They need cures and the systems fast enough to deliver them,” she asserts. The post, sponsored by AWS, emphasizes the role of technology in achieving these critical goals.
📝 About This Content
This article is based on insights shared by Drmarthaboeckenfeld on LinkedIn.
📅 Originally posted on June 3, 2026 | View original post on LinkedIn →